28岁男性难治性精神分裂症患者细胞色素P450代谢酶的药理学检测

A. Abdyrakhmanova, R. Nasyrova
{"title":"28岁男性难治性精神分裂症患者细胞色素P450代谢酶的药理学检测","authors":"A. Abdyrakhmanova, R. Nasyrova","doi":"10.52667/2712-9179-2022-2-1-81-88","DOIUrl":null,"url":null,"abstract":"Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C9, CYP3A4, CYP3A5 and CYP2D6) genes encoding cytochrome P450 enzymes involved in APs metabolism demonstrates the importance of this new personalized approach to the choice of APs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in a 28-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.","PeriodicalId":414041,"journal":{"name":"Personalized Psychiatry and Neurology","volume":"66 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Pharmacogenetic Testing of Cytochrome P450 Metabolizing Enzymes in 28-Year-Old Man with Treatment-Resistant Schizophrenia\",\"authors\":\"A. Abdyrakhmanova, R. Nasyrova\",\"doi\":\"10.52667/2712-9179-2022-2-1-81-88\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C9, CYP3A4, CYP3A5 and CYP2D6) genes encoding cytochrome P450 enzymes involved in APs metabolism demonstrates the importance of this new personalized approach to the choice of APs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in a 28-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.\",\"PeriodicalId\":414041,\"journal\":{\"name\":\"Personalized Psychiatry and Neurology\",\"volume\":\"66 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized Psychiatry and Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52667/2712-9179-2022-2-1-81-88\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized Psychiatry and Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52667/2712-9179-2022-2-1-81-88","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

精神分裂症是一种常见且具有社会意义的精神障碍,需要长期使用抗精神病药物(APs)。长期使用ap会增加某些患者发生药物不良反应(adr)和/或治疗耐药的风险。这可能是由于遗传决定的细胞色素P450酶对APs代谢的损害。药物遗传学检测(PGx)是一种识别发生ap诱导的adr高风险患者的方法。我们使用PGx搜索参与APs代谢的编码细胞色素P450酶的CYP1A2、CYP2C9、CYP3A4、CYP3A5和CYP2D6基因的低功能和无功能单核苷酸变异(snv) /多态性的经验表明,这种新的个性化方法对于药物遗传谱代谢不良的患者选择APs及其给药的重要性。本病例报告的主要目的是介绍一名28岁的难治性精神分裂症患者使用PGx的经验,该患者有ap诱发的不良反应的病史。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pharmacogenetic Testing of Cytochrome P450 Metabolizing Enzymes in 28-Year-Old Man with Treatment-Resistant Schizophrenia
Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C9, CYP3A4, CYP3A5 and CYP2D6) genes encoding cytochrome P450 enzymes involved in APs metabolism demonstrates the importance of this new personalized approach to the choice of APs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in a 28-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Predictive Pharmacogenetic Testing in Psychiatry: Pros and Cons The Frequency and Structure of Adverse Drug Reactions in the Pharmacotherapy of Epilepsy Application of Transcranial Magnetic Stimulation for the Treatment of Residual Catatonia Genetic Associations of the Polymorphic Variant of the DRD2 (rs1800497) Gene with Forms of Suicidal Behavior in Patients with Alcohol Dependence Atypical Structure of Broca's Area in a Patient with Primary Progressive Atrophy Syndrome at the Onset of Alzheimer's Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1